Reply to Comment on: Is this a 737 Max Moment for Brolucizumab?

Philip J. Rosenfeld; David J. Browning

doi:10.1016/j.ajo.2020.06.034

Reply to Comment on: Is this a 737 Max Moment for Brolucizumab?

Philip J. Rosenfeld, David J. Browning

Ophthalmology

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	446-447
Number of pages	2
Journal	American journal of ophthalmology
Volume	223
DOIs	https://doi.org/10.1016/j.ajo.2020.06.034
State	Published - Mar 2021

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/j.ajo.2020.06.034

Cite this

@article{03525044772f4e2099bf57953aa782e2,

title = "Reply to Comment on: Is this a 737 Max Moment for Brolucizumab?",

author = "Rosenfeld, {Philip J.} and Browning, {David J.}",

note = "Funding Information: Funding/Support: No funding or grant support. Financial disclosures: Dr Rosenfeld receives research support from Carl Zeiss Meditec, Inc. and Stealth BioTherapeutics, is a consultant for Apellis, Biogen, Boehringer-Ingelheim, Carl Zeiss Meditec, Chengdu Kanghong Biotech, EyePoint, Ocunexus Therapeutics, Ocudyne, and Unity Biotechnology, and has equity interest in Apellis, Valitor, Verana Health, and Ocudyne. Dr Browning receives research support from the DRCR Retina.net and Regeneron, has an equity interest in Zeiss-Meditec, and receives royalties from Springer Inc. The authors attest that they meet the current ICMJE criteria for authorship.",

year = "2021",

month = mar,

doi = "10.1016/j.ajo.2020.06.034",

language = "English (US)",

volume = "223",

pages = "446--447",

journal = "American Journal of Ophthalmology",

issn = "0002-9394",

publisher = "Elsevier USA",

}

TY - JOUR

T1 - Reply to Comment on

T2 - Is this a 737 Max Moment for Brolucizumab?

AU - Rosenfeld, Philip J.

AU - Browning, David J.

N1 - Funding Information: Funding/Support: No funding or grant support. Financial disclosures: Dr Rosenfeld receives research support from Carl Zeiss Meditec, Inc. and Stealth BioTherapeutics, is a consultant for Apellis, Biogen, Boehringer-Ingelheim, Carl Zeiss Meditec, Chengdu Kanghong Biotech, EyePoint, Ocunexus Therapeutics, Ocudyne, and Unity Biotechnology, and has equity interest in Apellis, Valitor, Verana Health, and Ocudyne. Dr Browning receives research support from the DRCR Retina.net and Regeneron, has an equity interest in Zeiss-Meditec, and receives royalties from Springer Inc. The authors attest that they meet the current ICMJE criteria for authorship.

PY - 2021/3

Y1 - 2021/3

UR - http://www.scopus.com/inward/record.url?scp=85096824441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096824441&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2020.06.034

DO - 10.1016/j.ajo.2020.06.034

M3 - Letter

C2 - 33187630

AN - SCOPUS:85096824441

VL - 223

SP - 446

EP - 447

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

ER -

Reply to Comment on: Is this a 737 Max Moment for Brolucizumab?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this